From 6 till 10 December 2022: HIGHLIGHTS ON BREAST CANCER
Your direct line with San Antonio
The San Antonio Breast Cancer Symposium (SABCS) is in its 45th year, and a lot of breast cancer research news is coming up. The MediMix team is onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen.
And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned!
With the support of Eli Lilly Benelux & Daiichi-Sankyo | AstraZeneca
Daily highlights
At the end of the San Antonio breast cancer symposium, Belgian experts were asked to compile a top three of the most important presentations. Unanimously chosen was the POSITIVE study, which showed that it is safe to temporarily interrupt adjuvant endocrine treatment in pregnancy. The DESTINY Breast02 study was also
In the last general session of this year’s San Antonio breast cancer symposium, prof François Duhoux from the university hospital Saint Luc, Brussels, gave an excellent summary of five exciting topics. Firstly, he discussed a phase 3 trial where platinum was added to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with
Day 4 at the San Antonio Breast Cancer Symposium (SABCS) is summarised here by Dr Kristof Van Berckelaer, gynaecologist at the University Hospital Antwerp. He presented results from the prospective ACOSOG Z11102 phase 2 trial evaluating the impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral
Day 3 at the San Antonio Breast Cancer Symposium (SABCS) focused on endocrine treatment in metastatic breast cancer, specifically exploring new treatment options for endocrine therapy after progression in first-line treatment. Prof dr Hannelore Denys from the University Hospital in Ghent made a summary of the most important presentations in
Day 2 at the San Antonio Breast Cancer Symposium (SABCS) 2022 focused on new data on the use of trastuzumab deruxtecan. The updated survival results of the DESTINY-Breast03 study were presented, as well as outcomes of trastuzumab deruxtecan in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with
It’s the first day at the San Antonio Breast Cancer Symposium (SABCS) 2022. And at this first day, Luminal Breast Cancer is the topic of the first general session, with exciting presentations both in primary and metastatic breast cancer. MediMix asked Prof Hans Wildiers from the University Hospital Gasthuisberg, KU
Project in the spotlight
At the San Antonio Breast Cancer Symposium, a Belgian poster caught our particular attention. Therefore, we are happy to place the project in the spotlight. Uptider is KU Leuven project for post-mortem tissue donation in breast cancer patients, to gain more insight into the evolutionary biology of metastatic breast cancer. In this video you hear and see everything about the project.
In-depth stories
The POLAR signature is a genetic classifier to define benefit of breast cancer radiotherapy. In this interview prof. dr. Per Karlsson from the Sahlgrenska Academy, Gothenburg, Sweden explained how clinical validation was performed via a patient-level meta-analysis of node-negative patients with ER+ / HER2-tumors from 3 clinical trials. The performance of the POLAR signature as a prognostic factor for locoregional recurrence in the absence of RT and as a predictor of benefit from radiotherapy following breast conserving surgery, was evaluated. He concludes with a glimpse into the future.
The 4-year follow up data of a pre-planned overall survival analysis of the monarchE trial were presented at SABCS as an oral presentation and are simultaneously published in The Lancet Oncology. Prof dr Patrick Neven from UZ Leuven, one of the co-authors of the monarchE trial, took the time to put the recent data in perspective. Besides explaining the clinically meaningful benefit, guidance on managing potential side effects is also given.
Poster selection
Dr Monica Cejuela, a medical oncologist from the Virgen del Rocio Hospital at Sevilla, presented in this poster real-world data on the use of the
Dr Mattia Rediti, medical oncologist and PhD student at the Breast Cancer Translational Research Laboratory of the Institut Jules Bordet (ULB), presented a poster on
Dr Maja Van Goistenhoven, a gynaecologist in formation at the KULeuven, presented a poster on the association between reproductive factors such as parity and age
Dr Karen Van Baelen, a PhD researcher at the KULeuven, is currently doing a research project on primary invasive lobular breast cancer. At the SABCS
Dr Edoardo Isnaldi and François Richard, both working at the Laboratory of Translational Breast Cancer Research at the KULeuven, presented their poster on the impact
Prof Duhoux from the oncology department of the King Albert II institute of the Cliniques Universitaires St.Luc, Brussels, presented a poster of the Belgian phase
Invasive lobular breast carcinoma (ILC) represents 5 to 15% of all invasive breast cancers. Recent studies showed the importance of tumour microenvironment (TME) heterogeneity on
The levonorgestrel intra-uterine device (LNG-IUD) is a widely used contraception method. Dr. Inés De Maeyer from UZ Leuven presented data exploring receptor expression in women
Tucatinib is an oral HER2-targeted therapy that was approved by the FDA in April 2020 for use in combination with trastuzumab and capecitabine for treatment
One year of adjuvant trastuzumab with 12 cycles of weekly paclitaxel represents the standard of care for patients with pathological tumour size ≤2cm, node-negative, HER2-positive
The 2020 ASCO-CAP guidelines recommended ER Low Positive as new reporting category for breast cancers with 1-10% of cells staining ER positive to acknowledge their
Dr. Vangoitsenhoven from KU Leuven evaluated how the adjuvant endocrine therapy policy at their hospital evolved over time. In a retrospective cohort study in premenopausal
Is the KI-67 level after neoadjuvant endocrine therapy associated with disease recurrence and survival in women with HR+ / HER2- early breast cancer? That question